USYMTRA Trademark

Trademark Overview


On Thursday, June 11, 2015, a trademark application was filed for USYMTRA with the United States Patent and Trademark Office. The USPTO has given the USYMTRA trademark a serial number of 86659989. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 4, 2019. This trademark is owned by Actavis, Inc.. The USYMTRA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
usymtra

General Information


Serial Number86659989
Word MarkUSYMTRA
Filing DateThursday, June 11, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 4, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 3, 2015

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 16, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameALLERGAN SALES, LLC
Party Type22 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameALLERGAN FINANCE, LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressPARSIPPANY, NJ 07054

Party NameActavis, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameActavis, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, February 4, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 4, 2019ABANDONMENT - NO USE STATEMENT FILED
Thursday, June 28, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 27, 2018EXTENSION 5 GRANTED
Thursday, June 14, 2018EXTENSION 5 FILED
Thursday, June 14, 2018TEAS EXTENSION RECEIVED
Wednesday, January 3, 2018ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, December 5, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 1, 2017EXTENSION 4 GRANTED
Friday, December 1, 2017EXTENSION 4 FILED
Friday, December 1, 2017TEAS EXTENSION RECEIVED
Saturday, July 8, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 7, 2017EXTENSION 3 GRANTED
Monday, June 12, 2017EXTENSION 3 FILED
Friday, July 7, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 28, 2017AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, June 12, 2017TEAS EXTENSION RECEIVED
Monday, January 30, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 16, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 15, 2016EXTENSION 2 GRANTED
Monday, October 31, 2016EXTENSION 2 FILED
Tuesday, November 15, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 31, 2016TEAS EXTENSION RECEIVED
Tuesday, June 28, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 24, 2016EXTENSION 1 GRANTED
Friday, June 24, 2016EXTENSION 1 FILED
Friday, June 24, 2016TEAS EXTENSION RECEIVED
Tuesday, December 29, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 3, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 3, 2015PUBLISHED FOR OPPOSITION
Wednesday, October 14, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, September 21, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 21, 2015ASSIGNED TO EXAMINER
Tuesday, June 16, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, June 15, 2015NEW APPLICATION ENTERED IN TRAM